img

Global Orphan Drugs for Adults Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical

Publisher : MRA | Format : PDF

Global Orphan Drugs for Adults Market Insights, Forecast to 2034

Orphan drugs for adults refer to medications that are specifically developed and approved for the treatment of rare diseases or conditions in adult populations. These drugs are designed to address medical needs in adult patients who have limited treatment options due to the rarity of their conditions.
Market Analysis and InsightsGlobal Orphan Drugs for Adults Market
Global Orphan Drugs for Adults market is expected to reach to US$ 61230 million in 2023, with a positive growth of %, compared with US$ 55670 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Orphan Drugs for Adults industry is evaluated to reach US$ 106140 million in 2033. The CAGR will be 9.6% during 2023 to 2033.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers
This report presents an overview of global Orphan Drugs for Adults market from 2018 to 2033, aiming to help readers to get a comprehensive understanding of global Orphan Drugs for Adults market with multiple angles. Items like regional revenue from 2018 to 2033 and companies’ revenue and gross margin from 2018 to 2023 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2033 are also highlighted.
Companies, Type, Application and Regions Listed in the Report



By Company


Abbvie
Orpharma
Amgen
Recordati
Novartis
Celgene
Amryt Pharma
Johnson & Johnson
GSK
Bristol-Myers Squibb Company
Roche Holding
Sanofi
Takeda
Pfizer
Vertex Pharmaceuticals
Segment by Type
Oncology Drugs
Gastrointestinal Drugs
Neurology Drugs
Cardio-vascular Drugs
Others

Segment by Application


Hospital Pharmacies
Retail pharmacies
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2033
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2033 globally
Chapter 5Product revenue analysis by application from 2018 to 2033 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2033 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2033
Chapter 7Product revenue analysis by type and application from 2018 to 2033 in Europe. Product revenue analysis of each country in Europe from 2018 to 2033
Chapter 8Product revenue analysis by type and application from 2018 to 2033 in China. Product revenue analysis of China from 2018 to 2033
Chapter 9Product revenue analysis by type and application from 2018 to 2033 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2033
Chapter 10Product revenue analysis by type and application from 2018 to 2033 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2033.
Chapter 11Companies’ outline, covering company’s basic information, major business, Orphan Drugs for Adults introduction, etc. Orphan Drugs for Adults Revenue and Gross Margin of each company from 2018 to 2023
Chapter 12MRAResearch’s Conclusions of Orphan Drugs for Adults
Chapter 13Methodology and Data Sources adopted by MRAResearch

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Orphan Drugs for Adults Market Size Growth Rate by Type, 2018 VS 2022 VS 2033
1.2.2 Oncology Drugs
1.2.3 Gastrointestinal Drugs
1.2.4 Neurology Drugs
1.2.5 Cardio-vascular Drugs
1.2.6 Others
1.3 Market by Application
1.3.1 Global Orphan Drugs for Adults Market Size Growth Rate by Application, 2018 VS 2022 VS 2033
1.3.2 Hospital Pharmacies
1.3.3 Retail pharmacies
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Orphan Drugs for Adults Market Perspective (2018-2033)
2.2 Global Orphan Drugs for Adults Growth Trends by Region
2.2.1 Orphan Drugs for Adults Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Orphan Drugs for Adults Historic Market Size by Region (2018-2023)
2.2.3 Orphan Drugs for Adults Forecasted Market Size by Region (2024-2033)
2.3 Orphan Drugs for Adults Market Dynamics
2.3.1 Orphan Drugs for Adults Industry Trends
2.3.2 Orphan Drugs for Adults Market Drivers
2.3.3 Orphan Drugs for Adults Market Challenges
2.3.4 Orphan Drugs for Adults Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Orphan Drugs for Adults by Players
3.1.1 Global Orphan Drugs for Adults Revenue by Players (2018-2023)
3.1.2 Global Orphan Drugs for Adults Revenue Market Share by Players (2018-2023)
3.2 Global Orphan Drugs for Adults Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Orphan Drugs for Adults, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Orphan Drugs for Adults Market Concentration Ratio
3.4.1 Global Orphan Drugs for Adults Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Orphan Drugs for Adults Revenue in 2022
3.5 Global Key Players of Orphan Drugs for Adults Head office and Area Served
3.6 Global Key Players of Orphan Drugs for Adults, Product and Application
3.7 Global Key Players of Orphan Drugs for Adults, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Orphan Drugs for Adults Breakdown Data by Type
4.1 Global Orphan Drugs for Adults Historic Market Size by Type (2018-2023)
4.2 Global Orphan Drugs for Adults Forecasted Market Size by Type (2024-2033)
5 Orphan Drugs for Adults Breakdown Data by Application
5.1 Global Orphan Drugs for Adults Historic Market Size by Application (2018-2023)
5.2 Global Orphan Drugs for Adults Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Orphan Drugs for Adults Market Size (2018-2033)
6.2 North America Orphan Drugs for Adults Market Size by Type
6.2.1 North America Orphan Drugs for Adults Market Size by Type (2018-2023)
6.2.2 North America Orphan Drugs for Adults Market Size by Type (2024-2033)
6.2.3 North America Orphan Drugs for Adults Market Share by Type (2018-2033)
6.3 North America Orphan Drugs for Adults Market Size by Application
6.3.1 North America Orphan Drugs for Adults Market Size by Application (2018-2023)
6.3.2 North America Orphan Drugs for Adults Market Size by Application (2024-2033)
6.3.3 North America Orphan Drugs for Adults Market Share by Application (2018-2033)
6.4 North America Orphan Drugs for Adults Market Size by Country
6.4.1 North America Orphan Drugs for Adults Market Size by Country: 2018 VS 2022 VS 2033
6.4.2 North America Orphan Drugs for Adults Market Size by Country (2018-2023)
6.4.3 North America Orphan Drugs for Adults Market Size by Country (2024-2033)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Orphan Drugs for Adults Market Size (2018-2033)
7.2 Europe Orphan Drugs for Adults Market Size by Type
7.2.1 Europe Orphan Drugs for Adults Market Size by Type (2018-2023)
7.2.2 Europe Orphan Drugs for Adults Market Size by Type (2024-2033)
7.2.3 Europe Orphan Drugs for Adults Market Share by Type (2018-2033)
7.3 Europe Orphan Drugs for Adults Market Size by Application
7.3.1 Europe Orphan Drugs for Adults Market Size by Application (2018-2023)
7.3.2 Europe Orphan Drugs for Adults Market Size by Application (2024-2033)
7.3.3 Europe Orphan Drugs for Adults Market Share by Application (2018-2033)
7.4 Europe Orphan Drugs for Adults Market Size by Country
7.4.1 Europe Orphan Drugs for Adults Market Size by Country: 2018 VS 2022 VS 2033
7.4.2 Europe Orphan Drugs for Adults Market Size by Country (2018-2023)
7.4.3 Europe Orphan Drugs for Adults Market Size by Country (2024-2033)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Orphan Drugs for Adults Market Size (2018-2033)
8.2 China Orphan Drugs for Adults Market Size by Type
8.2.1 China Orphan Drugs for Adults Market Size by Type (2018-2023)
8.2.2 China Orphan Drugs for Adults Market Size by Type (2024-2033)
8.2.3 China Orphan Drugs for Adults Market Share by Type (2018-2033)
8.3 China Orphan Drugs for Adults Market Size by Application
8.3.1 China Orphan Drugs for Adults Market Size by Application (2018-2023)
8.3.2 China Orphan Drugs for Adults Market Size by Application (2024-2033)
8.3.3 China Orphan Drugs for Adults Market Share by Application (2018-2033)
9 Asia (excluding China)
9.1 Asia Orphan Drugs for Adults Market Size (2018-2033)
9.2 Asia Orphan Drugs for Adults Market Size by Type
9.2.1 Asia Orphan Drugs for Adults Market Size by Type (2018-2023)
9.2.2 Asia Orphan Drugs for Adults Market Size by Type (2024-2033)
9.2.3 Asia Orphan Drugs for Adults Market Share by Type (2018-2033)
9.3 Asia Orphan Drugs for Adults Market Size by Application
9.3.1 Asia Orphan Drugs for Adults Market Size by Application (2018-2023)
9.3.2 Asia Orphan Drugs for Adults Market Size by Application (2024-2033)
9.3.3 Asia Orphan Drugs for Adults Market Share by Application (2018-2033)
9.4 Asia Orphan Drugs for Adults Market Size by Region
9.4.1 Asia Orphan Drugs for Adults Market Size by Region: 2018 VS 2022 VS 2033
9.4.2 Asia Orphan Drugs for Adults Market Size by Region (2018-2023)
9.4.3 Asia Orphan Drugs for Adults Market Size by Region (2024-2033)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Orphan Drugs for Adults Market Size (2018-2033)
10.2 Middle East, Africa, and Latin America Orphan Drugs for Adults Market Size by Type
10.2.1 Middle East, Africa, and Latin America Orphan Drugs for Adults Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Orphan Drugs for Adults Market Size by Type (2024-2033)
10.2.3 Middle East, Africa, and Latin America Orphan Drugs for Adults Market Share by Type (2018-2033)
10.3 Middle East, Africa, and Latin America Orphan Drugs for Adults Market Size by Application
10.3.1 Middle East, Africa, and Latin America Orphan Drugs for Adults Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Orphan Drugs for Adults Market Size by Application (2024-2033)
10.3.3 Middle East, Africa, and Latin America Orphan Drugs for Adults Market Share by Application (2018-2033)
10.4 Middle East, Africa, and Latin America Orphan Drugs for Adults Market Size by Country
10.4.1 Middle East, Africa, and Latin America Orphan Drugs for Adults Market Size by Country: 2018 VS 2022 VS 2033
10.4.2 Middle East, Africa, and Latin America Orphan Drugs for Adults Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Orphan Drugs for Adults Market Size by Country (2024-2033)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Abbvie
11.1.1 Abbvie Company Details
11.1.2 Abbvie Business Overview
11.1.3 Abbvie Orphan Drugs for Adults Introduction
11.1.4 Abbvie Revenue in Orphan Drugs for Adults Business (2018-2023)
11.1.5 Abbvie Recent Developments
11.2 Orpharma
11.2.1 Orpharma Company Details
11.2.2 Orpharma Business Overview
11.2.3 Orpharma Orphan Drugs for Adults Introduction
11.2.4 Orpharma Revenue in Orphan Drugs for Adults Business (2018-2023)
11.2.5 Orpharma Recent Developments
11.3 Amgen
11.3.1 Amgen Company Details
11.3.2 Amgen Business Overview
11.3.3 Amgen Orphan Drugs for Adults Introduction
11.3.4 Amgen Revenue in Orphan Drugs for Adults Business (2018-2023)
11.3.5 Amgen Recent Developments
11.4 Recordati
11.4.1 Recordati Company Details
11.4.2 Recordati Business Overview
11.4.3 Recordati Orphan Drugs for Adults Introduction
11.4.4 Recordati Revenue in Orphan Drugs for Adults Business (2018-2023)
11.4.5 Recordati Recent Developments
11.5 Novartis
11.5.1 Novartis Company Details
11.5.2 Novartis Business Overview
11.5.3 Novartis Orphan Drugs for Adults Introduction
11.5.4 Novartis Revenue in Orphan Drugs for Adults Business (2018-2023)
11.5.5 Novartis Recent Developments
11.6 Celgene
11.6.1 Celgene Company Details
11.6.2 Celgene Business Overview
11.6.3 Celgene Orphan Drugs for Adults Introduction
11.6.4 Celgene Revenue in Orphan Drugs for Adults Business (2018-2023)
11.6.5 Celgene Recent Developments
11.7 Amryt Pharma
11.7.1 Amryt Pharma Company Details
11.7.2 Amryt Pharma Business Overview
11.7.3 Amryt Pharma Orphan Drugs for Adults Introduction
11.7.4 Amryt Pharma Revenue in Orphan Drugs for Adults Business (2018-2023)
11.7.5 Amryt Pharma Recent Developments
11.8 Johnson & Johnson
11.8.1 Johnson & Johnson Company Details
11.8.2 Johnson & Johnson Business Overview
11.8.3 Johnson & Johnson Orphan Drugs for Adults Introduction
11.8.4 Johnson & Johnson Revenue in Orphan Drugs for Adults Business (2018-2023)
11.8.5 Johnson & Johnson Recent Developments
11.9 GSK
11.9.1 GSK Company Details
11.9.2 GSK Business Overview
11.9.3 GSK Orphan Drugs for Adults Introduction
11.9.4 GSK Revenue in Orphan Drugs for Adults Business (2018-2023)
11.9.5 GSK Recent Developments
11.10 Bristol-Myers Squibb Company
11.10.1 Bristol-Myers Squibb Company Company Details
11.10.2 Bristol-Myers Squibb Company Business Overview
11.10.3 Bristol-Myers Squibb Company Orphan Drugs for Adults Introduction
11.10.4 Bristol-Myers Squibb Company Revenue in Orphan Drugs for Adults Business (2018-2023)
11.10.5 Bristol-Myers Squibb Company Recent Developments
11.11 Roche Holding
11.11.1 Roche Holding Company Details
11.11.2 Roche Holding Business Overview
11.11.3 Roche Holding Orphan Drugs for Adults Introduction
11.11.4 Roche Holding Revenue in Orphan Drugs for Adults Business (2018-2023)
11.11.5 Roche Holding Recent Developments
11.12 Sanofi
11.12.1 Sanofi Company Details
11.12.2 Sanofi Business Overview
11.12.3 Sanofi Orphan Drugs for Adults Introduction
11.12.4 Sanofi Revenue in Orphan Drugs for Adults Business (2018-2023)
11.12.5 Sanofi Recent Developments
11.13 Takeda
11.13.1 Takeda Company Details
11.13.2 Takeda Business Overview
11.13.3 Takeda Orphan Drugs for Adults Introduction
11.13.4 Takeda Revenue in Orphan Drugs for Adults Business (2018-2023)
11.13.5 Takeda Recent Developments
11.14 Pfizer
11.14.1 Pfizer Company Details
11.14.2 Pfizer Business Overview
11.14.3 Pfizer Orphan Drugs for Adults Introduction
11.14.4 Pfizer Revenue in Orphan Drugs for Adults Business (2018-2023)
11.14.5 Pfizer Recent Developments
11.15 Vertex Pharmaceuticals
11.15.1 Vertex Pharmaceuticals Company Details
11.15.2 Vertex Pharmaceuticals Business Overview
11.15.3 Vertex Pharmaceuticals Orphan Drugs for Adults Introduction
11.15.4 Vertex Pharmaceuticals Revenue in Orphan Drugs for Adults Business (2018-2023)
11.15.5 Vertex Pharmaceuticals Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Orphan Drugs for Adults Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2033
Table 2. Key Players of Oncology Drugs
Table 3. Key Players of Gastrointestinal Drugs
Table 4. Key Players of Neurology Drugs
Table 5. Key Players of Cardio-vascular Drugs
Table 6. Key Players of Others
Table 7. Global Orphan Drugs for Adults Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2033
Table 8. Global Orphan Drugs for Adults Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 9. Global Orphan Drugs for Adults Market Size by Region (2018-2023) & (US$ Million)
Table 10. Global Orphan Drugs for Adults Market Share by Region (2018-2023)
Table 11. Global Orphan Drugs for Adults Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 12. Global Orphan Drugs for Adults Market Share by Region (2024-2033)
Table 13. Orphan Drugs for Adults Market Trends
Table 14. Orphan Drugs for Adults Market Drivers
Table 15. Orphan Drugs for Adults Market Challenges
Table 16. Orphan Drugs for Adults Market Restraints
Table 17. Global Orphan Drugs for Adults Revenue by Players (2018-2023) & (US$ Million)
Table 18. Global Orphan Drugs for Adults Revenue Share by Players (2018-2023)
Table 19. Global Top Orphan Drugs for Adults by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Orphan Drugs for Adults as of 2022)
Table 20. Global Orphan Drugs for Adults Industry Ranking 2021 VS 2022 VS 2023
Table 21. Global 5 Largest Players Market Share by Orphan Drugs for Adults Revenue (CR5 and HHI) & (2018-2023)
Table 22. Global Key Players of Orphan Drugs for Adults, Headquarters and Area Served
Table 23. Global Key Players of Orphan Drugs for Adults, Product and Application
Table 24. Global Key Players of Orphan Drugs for Adults, Product and Application
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Orphan Drugs for Adults Market Size by Type (2018-2023) & (US$ Million)
Table 27. Global Orphan Drugs for Adults Revenue Market Share by Type (2018-2023)
Table 28. Global Orphan Drugs for Adults Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 29. Global Orphan Drugs for Adults Revenue Market Share by Type (2024-2033)
Table 30. Global Orphan Drugs for Adults Market Size by Application (2018-2023) & (US$ Million)
Table 31. Global Orphan Drugs for Adults Revenue Share by Application (2018-2023)
Table 32. Global Orphan Drugs for Adults Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 33. Global Orphan Drugs for Adults Revenue Share by Application (2024-2033)
Table 34. North America Orphan Drugs for Adults Market Size by Type (2018-2023) & (US$ Million)
Table 35. North America Orphan Drugs for Adults Market Size by Type (2024-2033) & (US$ Million)
Table 36. North America Orphan Drugs for Adults Market Size by Application (2018-2023) & (US$ Million)
Table 37. North America Orphan Drugs for Adults Market Size by Application (2024-2033) & (US$ Million)
Table 38. North America Orphan Drugs for Adults Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 39. North America Orphan Drugs for Adults Market Size by Country (2018-2023) & (US$ Million)
Table 40. North America Orphan Drugs for Adults Market Size by Country (2024-2033) & (US$ Million)
Table 41. Europe Orphan Drugs for Adults Market Size by Type (2018-2023) & (US$ Million)
Table 42. Europe Orphan Drugs for Adults Market Size by Type (2024-2033) & (US$ Million)
Table 43. Europe Orphan Drugs for Adults Market Size by Application (2018-2023) & (US$ Million)
Table 44. Europe Orphan Drugs for Adults Market Size by Application (2024-2033) & (US$ Million)
Table 45. Europe Orphan Drugs for Adults Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 46. Europe Orphan Drugs for Adults Market Size by Country (2018-2023) & (US$ Million)
Table 47. Europe Orphan Drugs for Adults Market Size by Country (2024-2033) & (US$ Million)
Table 48. China Orphan Drugs for Adults Market Size by Type (2018-2023) & (US$ Million)
Table 49. China Orphan Drugs for Adults Market Size by Type (2024-2033) & (US$ Million)
Table 50. China Orphan Drugs for Adults Market Size by Application (2018-2023) & (US$ Million)
Table 51. China Orphan Drugs for Adults Market Size by Application (2024-2033) & (US$ Million)
Table 52. Asia Orphan Drugs for Adults Market Size by Type (2018-2023) & (US$ Million)
Table 53. Asia Orphan Drugs for Adults Market Size by Type (2024-2033) & (US$ Million)
Table 54. Asia Orphan Drugs for Adults Market Size by Application (2018-2023) & (US$ Million)
Table 55. Asia Orphan Drugs for Adults Market Size by Application (2024-2033) & (US$ Million)
Table 56. Asia Orphan Drugs for Adults Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 57. Asia Orphan Drugs for Adults Market Size by Region (2018-2023) & (US$ Million)
Table 58. Asia Orphan Drugs for Adults Market Size by Region (2024-2033) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Orphan Drugs for Adults Market Size by Type (2018-2023) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Orphan Drugs for Adults Market Size by Type (2024-2033) & (US$ Million)
Table 61. Middle East, Africa, and Latin America Orphan Drugs for Adults Market Size by Application (2018-2023) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Orphan Drugs for Adults Market Size by Application (2024-2033) & (US$ Million)
Table 63. Middle East, Africa, and Latin America Orphan Drugs for Adults Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 64. Middle East, Africa, and Latin America Orphan Drugs for Adults Market Size by Country (2018-2023) & (US$ Million)
Table 65. Middle East, Africa, and Latin America Orphan Drugs for Adults Market Size by Country (2024-2033) & (US$ Million)
Table 66. Abbvie Company Details
Table 67. Abbvie Business Overview
Table 68. Abbvie Orphan Drugs for Adults Product
Table 69. Abbvie Revenue in Orphan Drugs for Adults Business (2018-2023) & (US$ Million)
Table 70. Abbvie Recent Developments
Table 71. Orpharma Company Details
Table 72. Orpharma Business Overview
Table 73. Orpharma Orphan Drugs for Adults Product
Table 74. Orpharma Revenue in Orphan Drugs for Adults Business (2018-2023) & (US$ Million)
Table 75. Orpharma Recent Developments
Table 76. Amgen Company Details
Table 77. Amgen Business Overview
Table 78. Amgen Orphan Drugs for Adults Product
Table 79. Amgen Revenue in Orphan Drugs for Adults Business (2018-2023) & (US$ Million)
Table 80. Amgen Recent Developments
Table 81. Recordati Company Details
Table 82. Recordati Business Overview
Table 83. Recordati Orphan Drugs for Adults Product
Table 84. Recordati Revenue in Orphan Drugs for Adults Business (2018-2023) & (US$ Million)
Table 85. Recordati Recent Developments
Table 86. Novartis Company Details
Table 87. Novartis Business Overview
Table 88. Novartis Orphan Drugs for Adults Product
Table 89. Novartis Revenue in Orphan Drugs for Adults Business (2018-2023) & (US$ Million)
Table 90. Novartis Recent Developments
Table 91. Celgene Company Details
Table 92. Celgene Business Overview
Table 93. Celgene Orphan Drugs for Adults Product
Table 94. Celgene Revenue in Orphan Drugs for Adults Business (2018-2023) & (US$ Million)
Table 95. Celgene Recent Developments
Table 96. Amryt Pharma Company Details
Table 97. Amryt Pharma Business Overview
Table 98. Amryt Pharma Orphan Drugs for Adults Product
Table 99. Amryt Pharma Revenue in Orphan Drugs for Adults Business (2018-2023) & (US$ Million)
Table 100. Amryt Pharma Recent Developments
Table 101. Johnson & Johnson Company Details
Table 102. Johnson & Johnson Business Overview
Table 103. Johnson & Johnson Orphan Drugs for Adults Product
Table 104. Johnson & Johnson Revenue in Orphan Drugs for Adults Business (2018-2023) & (US$ Million)
Table 105. Johnson & Johnson Recent Developments
Table 106. GSK Company Details
Table 107. GSK Business Overview
Table 108. GSK Orphan Drugs for Adults Product
Table 109. GSK Revenue in Orphan Drugs for Adults Business (2018-2023) & (US$ Million)
Table 110. GSK Recent Developments
Table 111. Bristol-Myers Squibb Company Company Details
Table 112. Bristol-Myers Squibb Company Business Overview
Table 113. Bristol-Myers Squibb Company Orphan Drugs for Adults Product
Table 114. Bristol-Myers Squibb Company Revenue in Orphan Drugs for Adults Business (2018-2023) & (US$ Million)
Table 115. Bristol-Myers Squibb Company Recent Developments
Table 116. Roche Holding Company Details
Table 117. Roche Holding Business Overview
Table 118. Roche Holding Orphan Drugs for Adults Product
Table 119. Roche Holding Revenue in Orphan Drugs for Adults Business (2018-2023) & (US$ Million)
Table 120. Roche Holding Recent Developments
Table 121. Sanofi Company Details
Table 122. Sanofi Business Overview
Table 123. Sanofi Orphan Drugs for Adults Product
Table 124. Sanofi Revenue in Orphan Drugs for Adults Business (2018-2023) & (US$ Million)
Table 125. Sanofi Recent Developments
Table 126. Takeda Company Details
Table 127. Takeda Business Overview
Table 128. Takeda Orphan Drugs for Adults Product
Table 129. Takeda Revenue in Orphan Drugs for Adults Business (2018-2023) & (US$ Million)
Table 130. Takeda Recent Developments
Table 131. Pfizer Company Details
Table 132. Pfizer Business Overview
Table 133. Pfizer Orphan Drugs for Adults Product
Table 134. Pfizer Revenue in Orphan Drugs for Adults Business (2018-2023) & (US$ Million)
Table 135. Pfizer Recent Developments
Table 136. Vertex Pharmaceuticals Company Details
Table 137. Vertex Pharmaceuticals Business Overview
Table 138. Vertex Pharmaceuticals Orphan Drugs for Adults Product
Table 139. Vertex Pharmaceuticals Revenue in Orphan Drugs for Adults Business (2018-2023) & (US$ Million)
Table 140. Vertex Pharmaceuticals Recent Developments
Table 141. Research Programs/Design for This Report
Table 142. Key Data Information from Secondary Sources
Table 143. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Orphan Drugs for Adults Market Size Growth Rate by Type, 2018 VS 2022 VS 2033 (US$ Million)
Figure 2. Global Orphan Drugs for Adults Market Share by Type: 2022 VS 2033
Figure 3. Oncology Drugs Features
Figure 4. Gastrointestinal Drugs Features
Figure 5. Neurology Drugs Features
Figure 6. Cardio-vascular Drugs Features
Figure 7. Others Features
Figure 8. Global Orphan Drugs for Adults Market Size Growth Rate by Application, 2018 VS 2022 VS 2033 (US$ Million)
Figure 9. Global Orphan Drugs for Adults Market Share by Application: 2022 VS 2033
Figure 10. Hospital Pharmacies Case Studies
Figure 11. Retail pharmacies Case Studies
Figure 12. Others Case Studies
Figure 13. Orphan Drugs for Adults Report Years Considered
Figure 14. Global Orphan Drugs for Adults Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 15. Global Orphan Drugs for Adults Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 16. Global Orphan Drugs for Adults Market Share by Region: 2022 VS 2033
Figure 17. Global Orphan Drugs for Adults Market Share by Players in 2022
Figure 18. Global Top Orphan Drugs for Adults Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Orphan Drugs for Adults as of 2022)
Figure 19. The Top 10 and 5 Players Market Share by Orphan Drugs for Adults Revenue in 2022
Figure 20. North America Orphan Drugs for Adults Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 21. North America Orphan Drugs for Adults Market Share by Type (2018-2033)
Figure 22. North America Orphan Drugs for Adults Market Share by Application (2018-2033)
Figure 23. North America Orphan Drugs for Adults Market Share by Country (2018-2033)
Figure 24. United States Orphan Drugs for Adults Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 25. Canada Orphan Drugs for Adults Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 26. Europe Orphan Drugs for Adults Market Size YoY (2018-2033) & (US$ Million)
Figure 27. Europe Orphan Drugs for Adults Market Share by Type (2018-2033)
Figure 28. Europe Orphan Drugs for Adults Market Share by Application (2018-2033)
Figure 29. Europe Orphan Drugs for Adults Market Share by Country (2018-2033)
Figure 30. Germany Orphan Drugs for Adults Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. France Orphan Drugs for Adults Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. U.K. Orphan Drugs for Adults Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. Italy Orphan Drugs for Adults Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. Russia Orphan Drugs for Adults Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. Nordic Countries Orphan Drugs for Adults Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. China Orphan Drugs for Adults Market Size YoY (2018-2033) & (US$ Million)
Figure 37. China Orphan Drugs for Adults Market Share by Type (2018-2033)
Figure 38. China Orphan Drugs for Adults Market Share by Application (2018-2033)
Figure 39. Asia Orphan Drugs for Adults Market Size YoY (2018-2033) & (US$ Million)
Figure 40. Asia Orphan Drugs for Adults Market Share by Type (2018-2033)
Figure 41. Asia Orphan Drugs for Adults Market Share by Application (2018-2033)
Figure 42. Asia Orphan Drugs for Adults Market Share by Region (2018-2033)
Figure 43. Japan Orphan Drugs for Adults Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. South Korea Orphan Drugs for Adults Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. China Taiwan Orphan Drugs for Adults Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 46. Southeast Asia Orphan Drugs for Adults Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 47. India Orphan Drugs for Adults Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 48. Australia Orphan Drugs for Adults Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 49. Middle East, Africa, and Latin America Orphan Drugs for Adults Market Size YoY (2018-2033) & (US$ Million)
Figure 50. Middle East, Africa, and Latin America Orphan Drugs for Adults Market Share by Type (2018-2033)
Figure 51. Middle East, Africa, and Latin America Orphan Drugs for Adults Market Share by Application (2018-2033)
Figure 52. Middle East, Africa, and Latin America Orphan Drugs for Adults Market Share by Country (2018-2033)
Figure 53. Brazil Orphan Drugs for Adults Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 54. Mexico Orphan Drugs for Adults Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 55. Turkey Orphan Drugs for Adults Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 56. Saudi Arabia Orphan Drugs for Adults Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 57. Israel Orphan Drugs for Adults Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 58. GCC Countries Orphan Drugs for Adults Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 59. Abbvie Revenue Growth Rate in Orphan Drugs for Adults Business (2018-2023)
Figure 60. Orpharma Revenue Growth Rate in Orphan Drugs for Adults Business (2018-2023)
Figure 61. Amgen Revenue Growth Rate in Orphan Drugs for Adults Business (2018-2023)
Figure 62. Recordati Revenue Growth Rate in Orphan Drugs for Adults Business (2018-2023)
Figure 63. Novartis Revenue Growth Rate in Orphan Drugs for Adults Business (2018-2023)
Figure 64. Celgene Revenue Growth Rate in Orphan Drugs for Adults Business (2018-2023)
Figure 65. Amryt Pharma Revenue Growth Rate in Orphan Drugs for Adults Business (2018-2023)
Figure 66. Johnson & Johnson Revenue Growth Rate in Orphan Drugs for Adults Business (2018-2023)
Figure 67. GSK Revenue Growth Rate in Orphan Drugs for Adults Business (2018-2023)
Figure 68. Bristol-Myers Squibb Company Revenue Growth Rate in Orphan Drugs for Adults Business (2018-2023)
Figure 69. Roche Holding Revenue Growth Rate in Orphan Drugs for Adults Business (2018-2023)
Figure 70. Sanofi Revenue Growth Rate in Orphan Drugs for Adults Business (2018-2023)
Figure 71. Takeda Revenue Growth Rate in Orphan Drugs for Adults Business (2018-2023)
Figure 72. Pfizer Revenue Growth Rate in Orphan Drugs for Adults Business (2018-2023)
Figure 73. Vertex Pharmaceuticals Revenue Growth Rate in Orphan Drugs for Adults Business (2018-2023)
Figure 74. Bottom-up and Top-down Approaches for This Report
Figure 75. Data Triangulation
Figure 76. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries